Biopharmaceutical Consortium Members (CQDM)
The funding awarded by CQDM to innovative research projects is made possible by the financial support of our members:
- Leading pharmaceutical companies: Pfizer, Merck, GlaxoSmithKline, Roche, Boehringer Ingelheim, Janssen, Eli Lilly Canada, Novartis Pharma Canada, Servier, Sanofi Canada, Takeda, and AstraZeneca;
- The Ministère de l’Économie et de l’Innovation (MEI) of the Government of Quebec;
- The Business Led-Networks of Centres of Excellence (BL-NCE) program of the Government of Canada
Our members are actively involved in the activities of the biopharmaceutical consortium, sharing their deep expertise and providing invaluable support to help the CQDM carry out its mission. Their commitment is instrumental to the advancement of biopharmaceutical research, while demonstrating the unique value of a collaborative life sciences ecosystem that addresses unmet medical needs, with the ultimate goal of developing safer and more effective drugs.
Why become a member?
CQDM created a new type of yearly membership specifically for the biopharmaceutical sector, where members pay a fixed fee to access CQDM’s portfolio of new projects. Also, members now have the opportunity to fund projects consistent with their R&D focus. Benefits of the CQDM membership to the industry include:
Unique insight into innovative research in Quebec and Canada
- The right to review all submission associated with CQDM call for proposals (Quantum Leap Program).
- Access to all CQDM prospecting activities, including our pan-Canadian network.
- Opportunity to launch a call for proposals (managed by CQDM) focusing on an issue of specific interest to your organization.
- A seat on CQDM’s Industrial Members Committee, responsible for reviewing and preselecting all Quantum Leap proposals to CQDM.
Allocation of R&D funds to projects compatible with the focus areas of pharmaceutical members
- Opportunity to fund R&D projects in a specific field of interest to the pharmaceutical industry (including funds in addition to the annual contribution). The pharmaceutical members will only fund selected projects.
- Access to external scientific reviews and due diligence to settle issues and concerns expressed by participating members.
- Access to CQDM’s mentorship program for the funded technologies.
Exceptional leverage to fund R&D
- When a project is selected for funding, a pharmaceutical member may choose to share R&D costs with other participating pharmaceutical members or work on an exclusive basis.
- The participating member benefits exceptional leverage to fund R&D (reducing cost by 20% to 80%, depending on the project) with government agencies, CQDM financing partners and other pharmaceutical industry members.
- CQDM is a consortium recognized by income tax authorities for R&D. Accordingly, R&D expenses incurred by participating members are eligible to a tax credit of approximately 35% (in addition to the 20% to 80% cost saving stated above).
- Before launching a project, CQDM will negotiate rights for the participating pharmaceutical members (to be included in the research agreement with the funded entities). Yearly membership fees include negotiation services but exclude legal fees. The rights of the participating pharmaceutical members are tailored to their requirements for each funded project. Examples of rights granted to participating members on the technologies funded by CQDM may be provided upon request.